Filters
| Tests names and labs | Conditions | Genes, analytes, and microbes | Methods |
|---|---|---|---|
Molecular Genetics Laboratory London Health Sciences Centre Canada | 1 | 1 |
|
NGS Panel for Congenital Erythrocythosis or Familiar Polycythemia BloodGenetics Spain | 12 | 11 |
|
JAK2 Targeted Mutation Analysis (V617F) Genetics Center United States | 3 | 1 |
|
Genome-Nilou Lab Iran | 45 | 34 |
|
Invitae Inborn Errors of Immunity and Cytopenias Panel Invitae United States | 755 | 562 |
|
Invitae Familial Essential Thrombocythemia Panel Invitae United States | 9 | 3 |
|
Stroke, Cerebral Hemorrhage, Hemiplegia, and Migraine Panel PreventionGenetics, part of Exact Sciences United States | 345 | 159 |
|
Johns Hopkins Genomics DNA Diagnostic Laboratory Johns Hopkins Hospital United States | 250 | 155 |
|
Inherited Bone Marrow Failure Panel PreventionGenetics, part of Exact Sciences United States | 267 | 186 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Calreticulin Exon 9 Mutation, JAK2 V617F Quant and Exons 12-15 and MPL Mutation Analysis PathGroup United States | 9 | 3 |
|
JAK2 V617F Mutation Detect and Quant and JAK2 Exons12-15 Mutation Analysis PathGroup United States | 5 | 1 |
|
Calreticulin Exon 9 Mutation, MPL Mutation analysis and JAK2 Exons12-15 Mutation Analysis PathGroup United States | 9 | 3 |
|
Calreticulin Exon 9 Mutation and MPL Mutation analysis PathGroup United States | 8 | 2 |
|
Calreticulin Exon 9 Mutation and JAK2 V617F Quant and Exons 12-15 PathGroup United States | 8 | 2 |
|
Calreticulin Exon 9 Mutation, MPL and JAK2 V617F Quant PathGroup United States | 9 | 3 |
|
Calreticulin Exon 9 Mutation and JAK2 V617F Quant PathGroup United States | 8 | 2 |
|
PathGroup United States | 23 | 160 |
|
PathGroup United States | 18 | 160 |
|
BCR/ABL IS Quant CML and JAK2 V617F Quant and JAK2 Exon 12-15 PathGroup United States | 7 | 3 |
|
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.